Showing 261 - 280 results of 21,342 for search '(( significantly ((greatest decrease) OR (teer decrease)) ) OR ( significant decrease decrease ))', query time: 0.33s Refine Results
  1. 261
  2. 262
  3. 263
  4. 264
  5. 265

    NgR1 KO mice exhibited an increase in excitatory synapses and a decrease in inhibitory synapses, indicating an imbalance of synaptic transmission. by Jinwei Zhang (462455)

    Published 2025
    “…The inhibitory synaptic density of NgR1 mice showed a significant decrease when compared to WT mice (***P <  0.001). …”
  6. 266
  7. 267
  8. 268
  9. 269
  10. 270
  11. 271

    Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

    Published 2025
    “…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
  12. 272
  13. 273
  14. 274

    Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

    Published 2025
    “…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
  15. 275

    Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

    Published 2025
    “…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
  16. 276
  17. 277
  18. 278
  19. 279
  20. 280